Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma
Read more
01
July 2021
Enterome to present at upcoming investor conferences
Read more
16
June 2021
Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics
Read more
07
April 2021
Enterome to present at upcoming conferences
Read more
24
March 2021
Enterome receives FDA IND clearance for EO2463, an ‘OncoMimic’ based immunotherapy targeting liquid tumors
Read more
10
March 2021
Enterome strengthens its leadership team with the appointment of Anne Dagallier as Chief Business Officer
Read more
10
February 2021
Enterome presenting at upcoming investor meetings
Read more
23
September 2020
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
Read more
09
September 2020
First patient dosed in a phase 1/2 trial with EO2401, an innovative ‘OncoMimic’ based immunotherapy candidate targeting adrenal tumors
